2022 World Conference on Lung Cancer (ePosters)-EP08.02-067. Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

EP08.02-067. Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

Back to course

Pdf Summary

This study aims to investigate the efficacy and safety of concurrent treatment with aumolertinib and icotinib, two EGFR tyrosine kinase inhibitors (TKIs), as a first-line therapy for non-small cell lung cancer (NSCLC) with brain metastases. Brain metastases are found in up to 50% of advanced NSCLC patients and significantly affect prognosis. EGFR-TKIs have been recommended for NSCLC patients with EGFR mutations and brain metastases, with response rates reaching 60-80%. Aumolertinib and icotinib have both shown efficacy and safety for treating NSCLC with brain metastases.<br /><br />The study design involves dose escalation and dose expansion phases. The primary objective is to determine the maximum tolerated dose (MTD) in the dose escalation phase and feasibility in the dose expansion phase, defined as receiving combination therapy for six four-week cycles. Secondary objectives include assessing objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), duration of response (DoR), overall survival (OS), and intracranial ORR, DCR, PFS, and DoR. Patient selection criteria include age 18-75, EGFR-mutant stage IV NSCLC with baseline brain metastases, no prior systematic anti-cancer/EGFR-TKI therapy, and Eastern Cooperative Oncology Group physical status score of 0-1.<br /><br />The study will also assess the safety of the combination therapy, including the incidence and severity of adverse events and monitoring of clinical chemistry, hematology, vital signs, and electrocardiogram.<br /><br />This study is sponsored by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.<br /><br />In summary, this study aims to determine the efficacy, safety, and optimal dosage of concurrent aumolertinib and icotinib as first-line therapy for EGFR-mutant NSCLC with brain metastases. It has the potential to improve outcomes for NSCLC patients with this specific type of metastasis.

Asset Subtitle

Meijuan Huang

Meta Tag

Speaker Meijuan Huang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

efficacy

safety

concurrent treatment

aumolertinib

icotinib

EGFR tyrosine kinase inhibitors

first-line therapy

non-small cell lung cancer

NSCLC

brain metastases